TrialJournal for immunotherapy of cancer2022

Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial.

Yongxiang Xia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.